EGFR+ Lung Cancer

Two separate delays have been announced by Bristol-Myers Squibb and AstraZeneca in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

A review of data regarding PD-L1 expression as a predictive biomarker of response to checkpoint inhibition in lung cancer. 

Roy Herbst, MD, PhD, discusses the next steps with pembrolizumab in non-small cell lung cancer following its FDA approval, including combination regimens.  

Martin J. Edelman, MD, has joined Fox Chase Cancer Center as chair of the Department of Hematology/Oncology and deputy cancer center director for clinical research.

Claire Verschraegen, MD, discusses the design and findings of an early trial of avelumab and the future potential for the PD-L1 inhibitor in lung cancer.

Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC). 

A supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin has been granted priority review by the FDA as a treatment for patients with metastatic or advanced non-squamous non&ndash;small cell lung cancer without <em>EGFR</em> or <em>ALK</em> mutations and regardless of PD-L1 expression.

Mark G. Kris, MD,&nbsp;shares his thoughts on the prominent advancements in the field of lung cancer, how liquid biopsies are shaping treatment decisions, and his predictions for the years ahead.

PD-L1 expression is starting to be part of the standard of care in determining the appropriate treatment plan for newly diagnosed non-small cell lung cancer. However, testing for the biomarker is not always necessary for patients who have relapsed or who have small cell lung cancer.

Jared Weiss, MD, recently sat down with&nbsp;<em>Targeted Oncology</em>&nbsp;to discuss treatment considerations and options for patients with metastatic lung cancer based on 3 case scenarios.

Luciano Mutti, PhD, professor in cancer research, University of Salford, Manchester, discusses the current and future role of immunotherapy in mesothelioma.&nbsp;

Metastatic Non-Small Cell Lung Cancer with Alexander Drilon, MD

Metastatic Non-Small Cell Lung Cancer with Alexander Drilon, MD

Determining the PD-L1 status of a patient&rsquo;s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.

Jeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad&#39;s myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).

Patients with non-small cell lung cancer whose disease&nbsp;has metastasized to the brain can do without whole-brain&nbsp;radiotherapy, according to a study published in&nbsp;<em>Lancet.</em>

Howard L. &ldquo;Jack&rdquo; West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent&nbsp;<em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).

Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.

The majority of patients with non&ndash;small cell lung cancer do not harbor an actionable marker, calling for future research into optimal therapies and combinations for patients with non-driver adenocarcinoma.

The promising clinical efficacy seen with the combination of erlotinib and bevacizumab as a treatment for patients with <em>EGFR</em>-mutant non&ndash;small cell lung cancer warrants widespread consideration.